Elena Shagisultanova, MD, PhD, is working to uncover effective treatments for HER2-positive breast cancer patients by combining different drugs to counteract the cancer cells’ proliferation.
Merck (MRK) announced that the U.S. FDA has granted Breakthrough Therapy designation to sacituzumab tirumotecan for the treatment of patients with advanced or metastatic nonsquamous non-small cell ...